



ONWARD & UPWARD



UPDATES

@ATLAS


NEW FUND

ATLAS FUND X CLOSES AT \$280M HARD-CAP

[READ MORE](#)

NEW OFFICE

Atlas moves to Kendall Sq, the epicenter of biotech innovation



400 Technology Square
10th Floor
Cambridge, MA 02139

NEW WEBSITE

Visit our new website [here](#)

Ommer Chohan joins
Atlas Venture as CFO

View his bio [here](#)



HIGHLIGHTS

@ATLAS

INTELLIA THERAPEUTICS AND NOVARTIS FORM CRISPR PARTNERSHIP

Novartis partners with Intellia Therapeutics and Caribou Biosciences to develop new cell therapies using CRISPR genome editing technology

“Having the ability to bring a partner like Novartis early in the creation of the company both as an investor and a strategic collaborator is an important part of our model and a tribute to the Intellia team.”

JEAN-FRANCOIS FORMELA,
ATLAS PARTNER AND INTELLIA BOARD MEMBER

[READ THE PRESS RELEASE](#)


F-STAR + BMS
Partnership to develop novel cancer drugs targeting HER2

[READ MORE](#)

GRADUATION DAY

Padlock, Surface Oncology and LTI graduate from seed to Series A companies in the Atlas portfolio

[READ THE PRESS RELEASES: LTI, PADLOCK, SURFACE ONCOLOGY](#)




NATURE BIOTECH

Nature Biotech names five Atlas companies to its annual short list of “some of the best that academic research had to offer the startup world in 2014”

[READ MORE](#)

CONGRATS TO OUR FORMER TECHNOLOGY PARTNERS
ON THE LAUNCH OF THEIR NEW FUND



ADVANCES

@ATLAS

PEOPLE

RECRUITING ALL-STAR PLAYERS TO OUR PORTFOLIO

JEB KEIPER

NIMBUS THERAPEUTICS

[READ MORE](#)**RON RENAUD**

RANA THERAPEUTICS

[READ MORE](#)**MARK MANFREDI**

RAZE THERAPEUTICS

[READ MORE](#)**CHRISTIANA STAMOULIS**

UNUM THERAPEUTICS

[READ MORE](#)**MIKE MOYER**

RAZE THERAPEUTICS

[READ MORE](#)**MARK TEBBE**

QUARTET MEDICINE

[READ MORE](#)**DON NICHOLSON**

NIMBUS THERAPEUTICS

[READ MORE](#)**SAMANTHA TRUEX**

PADLOCK THERAPEUTICS

[READ MORE](#)

R&D PROGRESS

ADVANCING INNOVATIVE, HIGH-IMPACT SCIENCE

ZAFGEN

ANNOUNCES NEW WEIGHT LOSS AND SAFETY DATA FROM PHASE 2 TRIAL OF BELORANIB IN HIAO

[READ THE PRESS RELEASE](#)**NIMBUS**

INITIATES ITS PHASE 1 CLINICAL TRIAL FOR ITS ACC PROGRAM FOR THE TREATMENT OF NASH

[READ THE PRESS RELEASE](#)**UNUM**

INITIATES FIRST PHASE 1 CLINICAL TRIAL OF ITS ANTIBODY-COUPLED T-CELL RECEPTOR (ACTR) THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN LYMPHOMA

[READ THE PRESS RELEASE](#)**RODIN**

LI HUEI TSAI, SCIENTIFIC FOUNDER OF RODIN THERAPEUTICS, PUBLISHES A NEW STUDY OF EPIGENOMICS OF ALZHEIMER'S DISEASE PROGRESSION

[READ MORE](#)

BUSINESS DEVELOPMENT

COLLABORATING FOR SUCCESS

**ANNOVATION ACQUIRED**

The Medicines Company (NASDAQ: MDCO) acquires Annovation 2.5 years after its founding based on strong clinical results

[READ THE PRESS RELEASE](#)**F-STAR + BMS**

Partnership for novel HER2-targeted therapy with exclusive option to acquire F-star Alpha

[READ THE PRESS RELEASE](#)**INTELLIA + NOVARTIS**

Novartis collaborates with Intellia Therapeutics and Caribou Biosciences to explore making medicines and drug discovery tools with CRISPR genome editing technology, providing substantial non-equity funding over the next 5 years

[READ THE PRESS RELEASE](#)

FINANCINGS

POWERING UP OUR PORTFOLIO

**LTI RAISES SERIES A**

LTI raises \$20M in Series A financing

[READ THE PRESS RELEASE](#)**NIMBUS RAISES SERIES B**

Nimbus Therapeutics raises \$43M Series B financing from Atlas Ventures, Lightstone Ventures, and Pfizer Ventures

[READ THE PRESS RELEASE](#)**PADLOCK RAISES SERIES A**

Padlock Therapeutics secures \$23M Series A financing led by Atlas Venture

[READ THE PRESS RELEASE](#)**SURFACE RAISES SERIES A**

Surface Oncology announces \$35M Series A financing to advance next-generation cancer immunotherapies

[READ THE PRESS RELEASE](#)

LifeSciVC

**NATURE BIOTECH HONORS SOME OF
2014'S BEST ACADEMIC STARTUPS**

[READ THE BLOG POST](#)

**DATA SNAPSHOT: VC-BACKED
BIOPHARMA M&A 2014**

[READ THE BLOG POST](#)

**VENTURE-BACKED BIOTECH TODAY:
REFLECTIONS ON EXITS, FUNDING,
AND STARTUP FORMATION**

[READ THE BLOG POST](#)

**TORTOISE & HARE REVISITED: "TIME TO
IPO" FOR VC-BACKED STARTUPS**

[READ THE BLOG POST](#)

**BIOTECH CEOS: OBSERVATIONS IN
THERMODYNAMICS AND KINETICS**

[READ THE BLOG POST](#)